BG108245A - Имидазотриазинон-съдържащи състави за назално използване - Google Patents

Имидазотриазинон-съдържащи състави за назално използване

Info

Publication number
BG108245A
BG108245A BG108245A BG10824503A BG108245A BG 108245 A BG108245 A BG 108245A BG 108245 A BG108245 A BG 108245A BG 10824503 A BG10824503 A BG 10824503A BG 108245 A BG108245 A BG 108245A
Authority
BG
Bulgaria
Prior art keywords
imidazotriazinone
compositions containing
nasal application
nasal
application
Prior art date
Application number
BG108245A
Other languages
English (en)
Inventor
Peter Serno
Andreas Ohm
Wolfgang Barth
Richard-Josef Bauer
Hans-Martin Siefert
Dieter Zimmer
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of BG108245A publication Critical patent/BG108245A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до имидазотриазинон съдържащи състави за назално използване, които заедно с сGМР РDЕ-инхибитора включват незначително количество от един локален анестетик. а
BG108245A 2001-04-12 2003-10-09 Имидазотриазинон-съдържащи състави за назално използване BG108245A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10118306A DE10118306A1 (de) 2001-04-12 2001-04-12 Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation

Publications (1)

Publication Number Publication Date
BG108245A true BG108245A (bg) 2005-01-31

Family

ID=7681379

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108245A BG108245A (bg) 2001-04-12 2003-10-09 Имидазотриазинон-съдържащи състави за назално използване

Country Status (25)

Country Link
US (2) US6740306B2 (bg)
EP (1) EP1381368A2 (bg)
JP (1) JP2004525968A (bg)
KR (1) KR20030087072A (bg)
CN (1) CN1537004A (bg)
AR (1) AR035821A1 (bg)
BG (1) BG108245A (bg)
BR (1) BR0208813A (bg)
CA (1) CA2443639A1 (bg)
CZ (1) CZ20032752A3 (bg)
DE (1) DE10118306A1 (bg)
DO (1) DOP2002000373A (bg)
EC (1) ECSP034795A (bg)
EE (1) EE200300501A (bg)
GT (1) GT200200070A (bg)
HU (1) HUP0303877A3 (bg)
IL (1) IL158255A0 (bg)
MX (1) MXPA03009314A (bg)
NO (1) NO20034556L (bg)
PE (1) PE20021035A1 (bg)
PL (1) PL363033A1 (bg)
RU (1) RU2003133143A (bg)
SK (1) SK12682003A3 (bg)
UY (1) UY27256A1 (bg)
WO (1) WO2002083674A2 (bg)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348618T1 (de) * 2001-05-09 2007-01-15 Bayer Healthcare Ag Neue verwendung von 2-(2-ethoxy-5-(4-methyl- piperazin-1-sulfonyl)-phenyl)-5-methyl-7-propyl 3h-imidazo(5,1-f)(1,2,4)triazin-4-on
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
NZ555247A (en) * 2004-12-23 2010-06-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
EP1898879A1 (en) * 2005-06-23 2008-03-19 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
EP2167057A1 (en) * 2007-06-13 2010-03-31 Bayer HealthCare AG Pde inhibitors for the treatment of hearing impairment
AU2009257385A1 (en) * 2008-06-13 2009-12-17 Roxro Pharma, Inc. Pharmaceutical formulation of ketorolac for intranasal administration
US8277781B2 (en) * 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2020006606A1 (en) * 2018-07-05 2020-01-09 Helium 3 Resources Pty Ltd A pharmaceutical composition and method of use of same
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
EP4157449A4 (en) * 2020-05-26 2024-05-29 Strategic Drug Solutions, Inc. FORMULATIONS AND METHODS FOR THE TREATMENT OF ERECTILE DYSFUNCTION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
TW422837B (en) 1996-05-31 2001-02-21 Mochida Pharm Co Ltd Pyridocarbazole deivatives having cGMP-PDE inhibitory activity
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
WO1999015177A1 (en) 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
WO2000000199A1 (en) * 1998-06-26 2000-01-06 Nastech Pharmaceutical Company, Inc. Nasal delivery of sildenafil citrate
WO2000035434A2 (en) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders

Also Published As

Publication number Publication date
CA2443639A1 (en) 2002-10-24
RU2003133143A (ru) 2005-04-10
US20030022894A1 (en) 2003-01-30
AR035821A1 (es) 2004-07-14
UY27256A1 (es) 2002-11-29
NO20034556D0 (no) 2003-10-10
US6740306B2 (en) 2004-05-25
DE10118306A1 (de) 2002-10-17
WO2002083674A3 (de) 2003-01-09
NO20034556L (no) 2003-12-10
BR0208813A (pt) 2004-03-09
MXPA03009314A (es) 2004-03-10
GT200200070A (es) 2003-01-31
HUP0303877A3 (en) 2005-05-30
EP1381368A2 (de) 2004-01-21
KR20030087072A (ko) 2003-11-12
PL363033A1 (en) 2004-11-15
CZ20032752A3 (cs) 2004-01-14
EE200300501A (et) 2003-12-15
JP2004525968A (ja) 2004-08-26
DOP2002000373A (es) 2002-11-30
IL158255A0 (en) 2004-05-12
WO2002083674A2 (de) 2002-10-24
ECSP034795A (es) 2003-12-01
PE20021035A1 (es) 2002-11-29
US20040248891A1 (en) 2004-12-09
CN1537004A (zh) 2004-10-13
SK12682003A3 (sk) 2004-03-02
HUP0303877A2 (hu) 2004-03-29

Similar Documents

Publication Publication Date Title
MXPA03009314A (es) Composiciones que contienen imidazotriazinona para administracion nasal.
AP2001002204A0 (en) Pyrazole derivatives.
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
TNSN04141A1 (en) NEW COMPOUNDS - DDP - IV difluor
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
HUP0303886A3 (en) New film coating composition for coating of pharmaceutical compositions
AU2003228770A8 (en) Substituted pyrazolopyrimidines
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
PT1448853E (pt) Melhoramentos relacionados com branqueadores ópticos
IL163777A0 (en) Kinase inhibitors
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
BR0307595A (pt) Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico
IL160819A0 (en) Novel compounds and compositions as cathepsin inhibitors
IL159125A0 (en) Novel compounds and compositions as cathepsin inhibitors
MXPA04003755A (es) Endoprotesis vasculares.
CO5580729A2 (es) Composiciones nutricionales que comprenden cistationina
WO2003022844A3 (en) Synthesis of epothilones intermediates thereto and analogues thereof
DE60201074D1 (en) Pyrazolopyridinderivate
LT2003075A (en) Inhibitor of monoamine uptake
WO2002083108A3 (de) Zusammensetzungen enthaltend cgmp-pde-inhibitoren und lokalanästhetika zur nasalen applikation